A broad coalition of public policy, free-market, and grassroots organizations has sent a letter to Republican lawmakers urging support for three crucial pieces of patent legislation: the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act, the Patent Eligibility Restoration Act (PERA), and the RESTORE Patent Rights Act. These Read more…
FOR IMMEDIATE RELEASEFebruary 26, 2025 The Market Institute Supports the Reintroduction of the RESTORE Patent Rights Act Washington, D.C. – The Market Institute welcomes the reintroduction of the bipartisan RESTORE Patent Rights Act, sponsored by Senators Chris Coons (D-DE) and Tom Cotton (R-AR), alongside Representatives Nathaniel Moran (R-TX) and Madeleine Read more…
The United States is at a critical juncture in its competition with global rivals, particularly China, for leadership in critical and emerging technologies. This week, a coalition of conservative leaders sent a powerful message to Congress, urging action to safeguard America’s position as a global technology leader. The key to Read more…
The recent Congressional hearing on drug prices, patents, and the pharmaceutical industry has ignited a fervent debate. Unfortunately, much of the discourse has been overshadowed by misunderstandings and misinformation. A nuanced comprehension of the patent system and its pivotal role in drug innovation is essential for fostering informed discussions and Read more…
The U.S. International Trade Commission recently released a 500-page report exploring the complex nexus of intellectual property, COVID-19, and access to essential drugs and tests. Despite the extensive analysis, the report notably refrains from drawing a definitive conclusion, leaving policymakers to navigate the nuanced terrain of innovation and public health. Read more…
In a letter addressed to Congress, and organized by Competitive Enterprise Institute, the undersigned organizations express their strong concerns regarding the Inflation Reduction Act (IRA), particularly its provisions related to prescription drug price controls. The coalition argues that the IRA’s prescription drug price control regime is unnecessary, as it focuses Read more…
In the world of intellectual property, inventors and innovators have long relied on the protection of patents to safeguard their creations. However, in recent years, the Patent Trial and Appeal Board (PTAB) has become a contentious battleground where patents are challenged and, in some cases, invalidated. Market Institute President Charles Read more…
Just over a year ago, President Biden aimed to lead the nation towards innovation and collaboration, promoting research and unity to solve one of modern life’s biggest challenges—cancer. The United States has a long history of innovation, driven by a patent system that protects inventors and encourages investment in research Read more…
The National Institutes of Health has asked the public to submit written comments responding to a Workshop on Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer. See comment below: More innovation is fairly easy – create the right incentives For good or bad – people, businesses, investors, Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Policy looking at the problems with price setting drug prices. There are attempts by the Biden Administration to use “March In” rights to implement price controls – even at the expense of future innovation. He writes: “In Read more…